Authors: Benjamin Gaborit, Bernard Vanhove, Marie-Anne Vibet, Aurélie Le Thuaut, Karine Lacombe, Vincent Dubee, Florence Ader, Virginie Ferre, Eric Vicaut, Jéremie Orain, Morgane Le Bras, Anne Omnes, Laetitia Berly, Alexandra Jobert, Pascale Morineau-Le Houssine, Karine Botturi, Régis Josien, Laurent Flet, Nicolas Degauque, Sophie Brouard, Odile Duvaux, Alexandra Poinas, François Raffi, Eric Dailly, Thomas Guimard, Cécile Braudeau, Denis Malvy, Jean-François Faucher, Gabriela Illes Hajnal, Marc-Olivier Vareil, Mariam Roncato-Saberam, Laurent Vacher, Charlotte Biron, Maeva Lefebvre, Géraldine Gallot, Paul Le Turnier, Colin Deschanvres, Raphael Lecomte, Marie Chauveau, Anne-sophie Lecompte, Matthieu Grégoire, Ronan Bellouard, Guillaume Deslandes, Zineb Ouazene, Diane Bollens, Thibault Chiarabani, Jessica Krause-Le Garrec, Agathe Becker, Pierre Chauvelot, Anne Conrad, Tristan Ferry, Patrick Miailhes, Cécile Pouderoux, Sandrine Roux, Claire Triffault-Fillit

Venue: Trials

Type: Article

Abstract: Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach. Polyclonal neutralizing antibodies offers many advantages such as providing immediate immunity, consequently blunting an early pro-inflammatory pathogenic endogenous antibody response and lack of drug-drug interactions. By providing immediate immunity and inhibiting entry into cells, neutralizing antibody treatment is of interest for patient with COVID-19-induced moderate pneumonia. Convalescent... (read more)

DOI: 10.1186/s13063-021-05132-9